122384-88-7
中文名稱
糖尿病相關(guān)肽(胰島淀粉樣肽)(抗原)
英文名稱
AMYLIN, HUMAN
CAS
122384-88-7
分子式
C8H17O3*
分子量
161.219
MOL 文件
122384-88-7.mol
更新日期
2024/12/23 10:30:23
122384-88-7 結(jié)構(gòu)式
基本信息
中文別名
安林肽糊精肽
糖尿病相關(guān)肽
糖尿病相關(guān)肽(胰島淀粉樣肽)
糖尿病相關(guān)肽(胰島淀粉樣肽)(抗體)
糖尿病相關(guān)肽(胰島淀粉樣肽)(抗原)
糖尿病相關(guān)肽(胰島淀粉樣肽), ≥97% (HPLC)
英文別名
DAPIAPP
AMYLIN
AMLINTIDE
Insulinoma
DAP (HUMAN)
IAPP (HUMAN)
Human amylin
AMYLIN, HUMAN
DAP AMIDE, HUMAN
所屬類別
生物化工：多肽物理化學(xué)性質(zhì)
儲(chǔ)存條件-20°C
溶解度H2OPeptide Solubility and Storage Guidelines:1.??Calculate the length of the peptide.2.??Calculate the overall charge of the entire peptide according to the following table:3.??Recommended solution:
形態(tài)固體
顏色White to off-white
水溶解性Soluble to 5 mg/ml in water and in 5% acetic acid.
水溶解性Soluble to 5 mg/ml in water and in 5% acetic acid.
糖尿病相關(guān)肽(胰島淀粉樣肽)(抗原)價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-P1070 | 糖尿病相關(guān)肽(胰島淀粉樣肽)(抗原) Amylin, amide, human | 122384-88-7 | 500μg | 2400元 |
| 2024/11/08 | HY-P1070 | 糖尿病相關(guān)肽(胰島淀粉樣肽)(抗原) Amylin, amide, human | 122384-88-7 | 1mg | 3850元 |
| 2023/03/20 | HY-P1070 | 糖尿病相關(guān)肽(胰島淀粉樣肽)(抗原) Amylin, amide, human | 122384-88-7 | 5mg | 14000元 |
常見問題列表
生物活性
Amylin, amide, human 是一種 37 個(gè)氨基酸的多肽，是一種與胰島素共分泌的胰腺激素，在代謝和葡萄糖穩(wěn)態(tài)中發(fā)揮獨(dú)特作用。Amylin, amide, human 抑制胰高血糖素分泌，延遲胃排空，并作為飽腹感劑。體外研究
MCF-7 cells endogenously express human amylin receptor CTR1 and CTR2. Stimulation of the receptor with Amylin, amide, human results in the production of cAMP. Amylin, amide, human (0.001 nM-1000 μM) results in an EC 50 of 35.2±7.5 nM.
Cell Viability Assay
| Cell Line: | MCF-7 cells |
| Concentration: | 0.001 nM, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1 μM, 10μM, 100 μM, 1000 μM |
| Incubation Time: | |
| Result: | Resulted in the production of cAMP with an EC 50 of 35.2±7.5 nM. |
體內(nèi)研究
Amylin, amide, human (400 μg peptide /kg body weight) is injected by subcutaneous route in separated groups of swiss male mice. A typical PK curve for the free amylin is observed, with a half-time of 23 min.
| Animal Model: | Swiss male mice (8 weeks old) |
| Dosage: | 400 μg peptide /kg body weight (Pharmacokinetic Analysis) |
| Administration: | Subcutaneous route; 24 hours |
| Result: | Half-time of 23 min. |